The peptide RADA16-I itself has intrinsic properties which are beneficial for differential cell growth, proliferation and migration, and which influence wound healing processes . Delivery of an unmodified RADA16-I hydrogel results in immediate hemostasis, which has been proven by its application on cut wounds on the brain, liver, femoral artery, spinal cord, and skin . It is commercially available as PuraStat®, in the form of a pre-filled syringe, to stop small haemorrhages during surgeries. In addition, PuraSinus® (a 2.5% formulation of RADA16-I) was approved by the FDA in 2019 for use after nasal trauma and surgery as an intraoperative wound dressing to help achieve homeostasis, prevent adhesion and act as an adjunct in wound healing . It has also been tested for accelerating wound healing in human skin equivalents, where the authors compared RADA16-I with RADA16-I enriched with Epidermal Growth Factor (EGF) . The results showed that RADA16-I alone slightly increased wound closure and reepithelization compared to the control. Enhanced wound healing has also been observed in surgical periodontal defects after application of RADA16-I hydrogel . The authors indicate an increase in cell recruitment and angiogenesis in rats four weeks after surgery.